Headlines about Bio Blast Pharma (NASDAQ:ORPN) have been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bio Blast Pharma earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.6284123045365 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Separately, ValuEngine cut shares of Bio Blast Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

Shares of Bio Blast Pharma (ORPN) traded up 1.72% on Friday, reaching $0.59. 27,028 shares of the company’s stock were exchanged. Bio Blast Pharma has a 1-year low of $0.41 and a 1-year high of $1.87. The company’s market capitalization is $9.67 million. The stock’s 50-day moving average price is $0.62 and its 200-day moving average price is $0.65.

ILLEGAL ACTIVITY WARNING: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/02/bio-blast-pharma-orpn-earns-news-impact-score-of-0-21.html.

Bio Blast Pharma Company Profile

Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.

Insider Buying and Selling by Quarter for Bio Blast Pharma (NASDAQ:ORPN)

Receive News & Stock Ratings for Bio Blast Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio Blast Pharma Ltd. and related stocks with our FREE daily email newsletter.